By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
Panelists generally agree that UiPath's recent rally is not supported by fundamentals, with concerns around decelerating growth, thin margins, and integration risks. They question the stock's valuation as a high-growth AI play.
Risk: Integration risk and customer adoption of Agentic AI workflows
Opportunity: Potential revenue acceleration if UiPath successfully migrates its legacy RPA base to Agentic AI workflows
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
UiPath Inc. (NYSE:PATH) is one of the 10 Stocks Dominating With Powerful Gains.
UiPath climbed for a second day on Friday, adding 6.20 percent to close at $10.27 apiece, as investors began positioning portfolios ahead of the results of its earnings performance for the fiscal year 2027.
The company is scheduled to announce its financial and operating highlights via a conference call after market close on May 28.
A stock market graph. Photo by energepic.com
In its last earnings call, UiPath Inc. (NYSE:PATH) issued a 10.6 percent to 12 percent revenue growth target for the first quarter to a range of $395 million to $400 million, versus $357 million posted in the same period last year.
Annual recurring revenues (ARR) are projected to grow by 11.87 percent to 12.17 percent to a range of $1.894 billion to $1.899 billion, as compared with the $1.693 billion posted in the same comparable period.
Non-GAAP operating income, on the other hand, is targeted to be at $80 million, or a 14 percent jump from the $70 million posted year-on-year.
For the full fiscal 2027, UiPath Inc. (NYSE:PATH) expects revenues to be in the range of $1.754 billion to $1.759 billion, or an implied increase of 8.9 percent to 9.2 percent from the $1.6 billion in full fiscal 2026.
While we acknowledge the potential of PATH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.** **
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"UiPath's single-digit revenue growth guidance indicates a transition from a growth-stage disruptor to a low-growth legacy software firm, making the pre-earnings rally fundamentally fragile."
The 6% jump ahead of earnings suggests a 'buy the rumor' dynamic, but the underlying fundamentals are concerning. UiPath is decelerating; projecting ~9% revenue growth for fiscal 2027 is a far cry from the hyper-growth narrative once attached to the RPA sector. While non-GAAP operating income is improving, the stock is being priced as a legacy automation play rather than a high-octane AI winner. Investors are likely front-running a potential beat on low-bar guidance, but unless they demonstrate significant traction in Agentic AI workflows to justify a premium multiple, this rally looks like a classic liquidity trap before a potential re-valuation lower.
If UiPath surprises with a massive pivot toward autonomous agents that materially boosts net retention rates, the current valuation could look like a bargain compared to expensive, unproven AI infrastructure plays.
"N/A"
[Unavailable]
"PATH's single-digit revenue growth guidance and sub-5% operating margins suggest the RPA market has matured into a low-growth, low-margin business that doesn't justify current valuation without a credible AI catalyst the company hasn't yet articulated."
PATH's 6% pre-earnings pop on modest guidance is a classic momentum play, not a fundamental repricing. The FY2027 guidance of 8.9–9.2% revenue growth is decelerating sharply from historical RPA growth rates and sits below enterprise software benchmarks (~12–15%). ARR growth of 11.87–12.17% masks a concerning trend: revenue growth is lagging ARR expansion, suggesting either mix-shift to lower-ACV deals or customer concentration risk. The non-GAAP operating margin target (4.6% on FY2027 midpoint) remains razor-thin for a mature SaaS company. The article itself admits PATH faces 'less upside potential' than alternatives—a stunning editorial admission buried in marketing copy.
If PATH is successfully pivoting to AI-assisted automation and winning large enterprise deals in 2027, the low guidance could be conservative, and the stock could re-rate 25–40% on a beat. The market may reward execution over absolute margin levels if growth re-accelerates.
"UiPath's upside hinges on durable enterprise automation demand and meaningful margin expansion; otherwise the valuation faces downside risk from slower growth or margin compression."
UiPath's pre-earnings rally reflects solid ARR growth around 12% and a guided mid-single-digit revenue rise for fiscal 2027, signaling durable demand for enterprise automation. Yet profitability remains understated: non-GAAP operating income around $80 million on roughly $1.75 billion revenue implies sub-5% margins and a long road to meaningful FCF. Growth is credible but not explosive, and ARR momentum could waver if enterprise budgets tighten or AI spending shifts. The stock’s up move also hinges on market risk appetite for AI names and competitive pressure from larger cloud players. Key watchpoints: bookings mix, gross margins, and customer retention as earnings arrive.
The strongest counter: PATH’s growth is still modest for a high-growth story, and if Q2 softens or AI budgets contract, valuation could compress faster than peers due to its thin margin base and competitive pressures.
"The revenue-ARR gap is likely a byproduct of a consumption-based pricing transition rather than customer concentration risk."
Claude, you’re missing the forest for the trees regarding the ARR-to-revenue lag. It isn't just a mix-shift; it’s a structural transition to consumption-based pricing models which inherently creates a temporary revenue headwind. If UiPath successfully migrates its legacy RPA base to Agentic AI workflows, that 'lag' will evaporate as usage spikes. The real danger isn't the margin profile, but the integration risk—if they can't force-multiply their existing seat count into autonomous agent seats, the valuation collapses.
[Unavailable]
"The consumption-model explanation for ARR-revenue lag is speculative; customer demand for agentic pivot remains the unproven lynchpin."
Gemini's consumption-model thesis is plausible but unverified by the article. The ARR-revenue lag could equally signal customer churn or deal-size compression—consumption models typically *accelerate* revenue once adoption scales, not lag it. More critically: nobody's asked whether UiPath's installed base actually wants autonomous agents, or if they're locked into legacy workflows. That adoption risk dwarfs the pricing-model explanation.
"Pivot alone isn't a guaranteed path to margin expansion or stock upside."
Gemini's ARR-to-revenue lag thesis hinges on a structural shift that may not materialize. Even with Agentic AI migration, revenue recognition and contract velocity depend on cross-sell and usage expansion, not just seat counts. The real risk is integration complexity and customer inertia; this could keep revenue growth subdued even if ARR accelerates, undermining the implied pivot premium. A pivot alone isn't a guaranteed path to margin expansion or multiple upside.
Panelists generally agree that UiPath's recent rally is not supported by fundamentals, with concerns around decelerating growth, thin margins, and integration risks. They question the stock's valuation as a high-growth AI play.
Potential revenue acceleration if UiPath successfully migrates its legacy RPA base to Agentic AI workflows
Integration risk and customer adoption of Agentic AI workflows